

Date: May 17, 2019

To The Manager, Listing Department, <b>National Stock Exchange of India Limited, (NSE)</b> Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To The Department of Corporate Service, <b>BSE Limited, (BSE)</b> Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
<b>Scrip Code-LINCOLN</b>	<b>Scrip Code-531633</b>

Dear Sir / Madam,

**Sub.: Intimation of Board Meeting and Closure of Trading Window.**

We would like to inform that the Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 30, 2019 at the Registered Office of the Company inter-alia to consider the following Businesses:


1. Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year Ended on March 31, 2019.
2. Recommendation of Dividend on Equity Shares of the Company for the Financial Year Ended on March 31, 2019, if any,
3. Any other matter with the approval of the chair.

Further, in continuation to our disclosure on Closure of Trading Window dated April 3, 2019, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, it may be noted that the trading window has been closed for Designated Persons viz Directors, identified Employees, KMPs, Promoter and Promoter Group of the Company and its subsidiaries including Immediate Relatives of the Designated Persons of the Company and its subsidiaries and for the Connected Persons from April 4, 2019 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
**FOR LINCOLN PHARMACEUTICALS LIMITED**

  
(AUTHORISED SIGNATORY)

